Recombinant IL17A (Netakimab Biosimilar) antibody

Catalog No. ABIN7488161

The Mammalian Cells Monoclonal anti-IL17A (Netakimab Biosimilar) antibody has been validated for ELISA. It is suitable to detect IL17A (Netakimab Biosimilar) in samples from Human.

Quick Overview for Recombinant IL17A (Netakimab Biosimilar) antibody (ABIN7488161)

Target: IL17A (Netakimab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This IL17A (Netakimab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-IL17A (Netakimab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Netakimab Biosimilar - Anti-IL17A mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for IL17A (Netakimab Biosimilar)

Target: IL17A (Netakimab Biosimilar)

Target Type: Biosimilar

Background: AG1-25
Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy.

CAS-No: 1796570-08-5